查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1992478

腸溶膠囊市場：全球市場按應用、材料、分銷管道和最終用戶分類的預測－2026-2032年

Enteric Capsule Market by Application, Material Type, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，腸溶膠囊市場價值將達到 7.5525 億美元，到 2026 年將成長至 7.9816 億美元，到 2032 年將達到 11.3521 億美元，複合年成長率為 5.99%。

主要市場統計數據
基準年 2025 7.5525億美元
預計年份：2026年 7.9816億美元
預測年份 2032 11.3521億美元
複合年成長率 (%) 5.99%

清晰簡潔地介紹了腸溶膠囊技術對於配方準確性和跨行業應用的重要性。

隨著製造商和終端用戶對精準給藥、更高穩定性和更佳患者及消費者體驗的需求日益成長，腸溶膠囊已成為許多行業中重要的製劑技術。這些膠囊旨在耐受低pH環境，並在達到目標pH閾值時溶解，使活性成分能夠順利通過胃部並釋放。在需要保護藥物免受胃部環境影響、掩蓋藥物味道或實現標靶腸道給藥等因素對臨床和商業性結果產生影響的情況下，這項技術的重要性日益凸顯。

材料創新、更嚴格的法規和數位化分銷如何改變腸溶膠囊產業的格局和產業策略？

腸溶膠囊技術正經歷一場變革，其驅動力包括材料創新、永續性需求以及分銷管道的數位化。替代聚合物的進步和生產控制的改進，提高了溶出曲線的一致性，同時也解決了人們對動物性材料的擔憂。因此，在配方相容性和消費者偏好方面，製造商擴大採用羥丙基甲基纖維素和其他非動物性原料。

評估美國於 2025 年實施的關稅對腸溶膠囊供應鏈和生產選擇的累積營運和採購影響。

2025年關稅和貿易措施的實施對腸溶膠囊生態系統產生了連鎖反應，影響成本、籌資策略和生產能力的地理分佈。原料、中間體和成品的關稅調整促使採購團隊重新審視與供應商的契約，並評估近岸外包方案，以降低跨境關稅風險。這種調整對那些歷來依賴特定供應區域的原料尤其顯著。

關鍵的細分洞察揭示了應用需求、材料選擇、通路和最終用戶畫像如何相互交織並影響策略決策。

詳細的細分分析突顯了應用、材料類型、分銷管道和終端用戶趨勢如何轉化為清晰的策略重點和商業性成果。在考慮應用時，相關人員必須協調動物用藥品、食品飲料、營養補充劑和製藥等行業的技術要求。在營養補充劑領域，草藥產品和維生素補充劑的配方重點有所不同；在製藥領域，非處方藥和處方藥的考量因素也各不相同。這意味著產品開發人員和採購團隊必須選擇合適的原料並調整溶解特性，以滿足預期的最終用途，從而達到性能和監管要求。

從詳細的區域觀點解釋為什麼美洲、歐洲、中東和非洲以及亞太地區都需要各自獨特的供應和市場進入策略。

了解區域趨勢對於掌握腸溶膠囊市場的滲透管道和競爭優勢至關重要。在美洲，成熟的製藥業、強勁的膳食補充劑消費趨勢以及完善的物流基礎設施（支持快速分銷和大規模生產）正在推動市場發展。監管合規、以患者為中心的設計以及支持臨床供應鏈和零售網路的夥伴關係是該地區的關鍵優先事項。

從公司層級分析關鍵市場動態，說明技術差異化、策略夥伴關係和供應韌性如何決定腸溶膠囊市場的領導地位。

腸溶膠囊技術的競爭動態由專業化、夥伴關係以及為確保可靠的原料供應和提升製劑性能而展開的競爭所決定。領先的製造商透過專有的材料混合物、更精準的溶離度控制以及檢驗的生產流程來降低產品變異性並支持監管申報，從而實現差異化。通常，成功取決於整合的價值鏈，其中原料供應商、膠囊製造商和下游製劑製造商緊密合作，以降低規模化生產的風險並確保最終產品性能的穩定性。

為產業領導者提供實用建議，以結合材料創新、敏捷製造和策略夥伴關係來建立競爭優勢。

腸溶膠囊領域的領導企業應採取整合策略，平衡材料創新、供應鏈韌性和監管準備，以掌握新的機會。投資開發非動物性替代聚合物，並以多種活性成分檢驗這些材料，將有助於開拓新的客戶群，同時降低因動物性明膠原料供應衝擊而帶來的風險。此外，建立合格生產和多基地認證體系，能夠實現不同工廠間生產規模的快速調整，進而降低關稅和貿易風險。

本文描述了一種嚴謹的混合方法調查方法，解釋了主要訪談、技術文獻綜述和資料檢驗如何支持本報告的研究結果。

本分析採用混合研究方法，結合一手資料和二手資料，並運用三角驗證法確保結果的準確性和有效性。一手資料來源包括對配方科學家、採購經理、法規專家和分銷合作夥伴的結構化檢驗，以及盡可能進行的現場考察和生產流程的直接觀察。這些工作為了解不同應用領域的材料選擇因素、供應鏈優先事項和客戶決策標準提供了定性見解。

簡潔的結論整合了策略重點和營運要求，供相關人員在應對腸溶膠囊市場的複雜性時參考。

總之，腸溶膠囊技術在材料科學、法規遵循和商業分銷動態的交匯點佔據著戰略地位。其應用趨勢受到以下因素的影響：轉向非動物性聚合物、監管機構對可追溯性的日益成長的要求，以及在不斷變化的貿易政策下建立具有韌性的供應鏈的需求。這些因素影響著從早期配方開發到採購和下游分銷的決策，需要研發、生產和銷售團隊之間制定協調一致的策略。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 腸溶膠囊市場：依應用領域分類

  • 動物用藥品
  • 食品/飲料
  • 營養保健品
    • 草本產品
    • 維生素和補充劑
  • 製藥
    • 非處方藥
    • 處方藥

第9章 腸溶膠囊市場：依材料類型分類

  • 明膠
    • 牛明膠
    • 豬明膠
  • 羥丙基甲基纖維素

第10章 腸溶膠囊市場：依通路分類

  • 線上
  • 離線

第11章 腸溶膠囊市場：依最終用戶分類

  • 醫院和診所
  • 網路藥房
  • 藥局/藥局
    • 連鎖藥局
    • 獨立經營藥房
  • 研究機構

第12章 腸溶膠囊市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 腸溶膠囊市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 腸溶膠囊市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國腸溶膠囊市場

第16章：中國腸溶膠囊市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Aenova Group
  • AstraZeneca
  • BASF SE
  • CapsCanada Corp
  • CAPTEK Softgel International
  • Catalent, Inc.
  • Cipla Limited
  • Colorcon, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • EuroCaps Ltd.
  • Evonik Industries
  • Fuji Capsule Co., Ltd.
  • Gelita AG
  • Johnson & Johnson
  • Lonza Group Ltd.
  • Lupin Limited
  • Merck & Co.
  • Natural Capsules Limited
  • Novartis AG
  • Pfizer Inc.
  • Procaps Group
  • Sirio Pharma Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-3204321AF70B

The Enteric Capsule Market was valued at USD 755.25 million in 2025 and is projected to grow to USD 798.16 million in 2026, with a CAGR of 5.99%, reaching USD 1,135.21 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 755.25 million
Estimated Year [2026] USD 798.16 million
Forecast Year [2032] USD 1,135.21 million
CAGR (%) 5.99%

A clear and concise introduction that explains why enteric capsule technologies matter for formulation precision and cross-sector applications

Enteric capsules have become a strategic formulation technology across multiple industries as manufacturers and end users seek precise dose delivery, improved stability, and enhanced patient or consumer experience. These capsules are engineered to withstand low pH environments and dissolve at targeted pH thresholds, enabling active ingredients to be released beyond the stomach. The technology is increasingly relevant where protection from gastric conditions, taste masking, or targeted intestinal delivery drives clinical and commercial outcomes.

Emerging preferences for plant-based excipients, regulatory scrutiny on cross-contamination, and expanding applications beyond traditional pharmaceuticals are reshaping how R&D teams evaluate material selection and production scale. As a result, stakeholders across animal health, food and beverage, nutraceuticals and pharmaceutical applications are re-evaluating formulation strategies and vendor relationships to achieve consistent performance across global distribution channels.

Throughout this study, we focus on how material innovations, distribution complexities, and evolving end-user demands interact to influence technology adoption and product differentiation. By integrating technical performance with practical considerations such as manufacturability and regulatory fit, this introduction sets the stage for deeper analysis across segmentation, geography, and competitive behavior.

How material innovation, regulatory tightening, and digital distribution are reshaping the enteric capsule landscape and industrial strategies

The landscape for enteric capsule technologies is undergoing transformative shifts driven by material innovation, sustainability expectations, and digitalized distribution. Advances in alternative polymers and improved manufacturing controls are enabling higher consistency in dissolution profiles while addressing concerns over animal-derived materials. This is prompting manufacturers to adopt hydroxypropyl methylcellulose and other non-animal feedstocks where formulation compatibility and consumer preferences require it.

Concurrently, regulatory frameworks and quality assurance benchmarks are tightening, leading to more rigorous documentation requirements and increased scrutiny of supply chains. These regulations are encouraging stronger traceability, end-to-end testing and closer collaboration between raw material suppliers and finished-dose manufacturers. In parallel, supply chain disruptions and a renewed focus on resilience have accelerated localization strategies and the diversification of sourcing to mitigate single-source dependencies.

Digital channels and e-commerce continue to redefine market access, creating direct engagement opportunities with end users and new pathways for smaller innovators to scale. As a result, incumbents and new entrants alike are shifting investment toward formulation science, manufacturing flexibility, and customer-centric distribution strategies to capture growth in both traditional pharmaceutical and adjacent markets such as nutraceuticals and animal health.

Assessing the cumulative operational and sourcing consequences of United States tariffs enacted in 2025 on enteric capsule supply chains and manufacturing choices

The imposition of tariffs and trade measures in 2025 has had a cascading influence on the enteric capsule ecosystem, affecting costs, sourcing strategies, and the geographic distribution of manufacturing capacity. Tariff adjustments on raw materials, intermediate components and finished goods have prompted procurement teams to revisit supplier contracts and to evaluate nearshoring options to reduce exposure to cross-border duties. This recalibration has been particularly active for materials that have historically depended on concentrated supply regions.

In response, manufacturers have increased their emphasis on supplier qualification, dual-sourcing strategies, and flexible production agreements that allow rapid shifting of volumes between facilities. Producers are also negotiating longer-term purchase agreements that incorporate duty mitigation clauses and exploring tariff engineering - reclassifying inputs or reconfiguring product flows to optimize customs treatments under prevailing rules.

These adaptations are influencing investment decisions for capital equipment and local manufacturing partnerships. Companies focused on high-value, regulated applications such as prescription pharmaceuticals are prioritizing compliance and supply continuity, whereas firms in nutraceuticals and food and beverage applications often emphasize cost-efficiency and distribution agility. Overall, the cumulative effect of tariffs in 2025 has accelerated operational shifts toward resilience-oriented supply chain designs and strategic procurement frameworks.

Critical segmentation insights revealing how application needs, material choices, distribution paths and end-user profiles intersect to shape strategic decisions

A granular view of segmentation underscores how application, material type, distribution channel and end-user dynamics map to distinct strategic priorities and commercial outcomes. When considering application, stakeholders must align technical requirements across animal health, food and beverages, nutraceuticals and pharmaceuticals; within nutraceuticals, formulation priorities diverge between herbal products and vitamins and supplements, while pharmaceuticals split considerations between over-the-counter and prescription drugs. This means product developers and procurement teams must tailor material selection and dissolution characteristics to the intended end use to meet performance and regulatory expectations.

Material type drives both formulation behavior and market positioning. Gelatin remains a critical material choice with differentiation between bovine and porcine gelatin variants influencing sourcing, religious compliance, and labeling. Hydroxypropyl methylcellulose represents a non-animal alternative with distinct processing and dissolution attributes that appeal to manufacturers targeting broader consumer segments. These material choices intersect with distribution channel strategies: direct sales, distributors and e-commerce each present different lead-time, packaging and regulatory disclosure requirements, and distributors themselves vary by national and regional reach while e-commerce channels include brand websites, marketplaces and online pharmacies with varying compliance implications.

End-user segmentation further refines demand profiles; hospitals and clinics, online pharmacies, pharmacies and drug stores, and research institutes exhibit divergent procurement cycles, quality expectations and order volumes. Pharmacies and drug stores break down into chain and independent formats, with chains typically emphasizing standardized SKUs and independents often prioritizing differentiated products tailored to local preferences. Taken together, these segmentation dimensions reveal complex interactions that require nuanced commercial strategies and product development roadmaps to optimize market fit and supplier relationships.

A nuanced regional perspective that explains how Americas, Europe Middle East Africa, and Asia-Pacific each require tailored supply and go-to-market strategies

Regional dynamics are central to understanding adoption pathways and competitive advantage in enteric capsule markets. In the Americas, commercial momentum is shaped by a mature pharmaceutical sector, strong nutraceutical consumption patterns and an established logistics infrastructure that supports rapid distribution and large-scale manufacturing. This region emphasizes regulatory compliance, patient-centric design, and partnerships that support clinical supply chains and retail networks.

Europe, Middle East & Africa presents a heterogeneous landscape characterized by rigorous regulatory environments in many European countries, diverse cultural and religious considerations that influence material selection, and variable manufacturing capacities across the Middle East and Africa. The region rewards companies that demonstrate regulatory expertise, localized supply chains and sensitivity to sourcing constraints related to animal-derived materials.

Asia-Pacific remains a high-velocity environment with a concentration of manufacturing capability, deep supplier networks, and growing domestic demand for both pharmaceutical and nutraceutical products. Market participants in this region frequently combine scale-focused production strategies with rapid innovation cycles. Taken together, these regional differences necessitate bespoke go-to-market and sourcing strategies that reflect local regulatory regimes, consumer preferences and manufacturing ecosystems.

Key company-level dynamics showing how technical differentiation, strategic partnerships, and supply resilience determine leadership in enteric capsule markets

Competitive dynamics in enteric capsule technologies are defined by specialization, partnerships, and a race to secure reliable raw material streams while advancing formulation performance. Leading manufacturers are differentiating through proprietary material blends, enhanced dissolution control, and validated manufacturing processes that reduce variability and support regulatory submissions. In many cases, success depends on integrated value chains where material suppliers, capsule manufacturers and downstream formulators collaborate closely to de-risk scale-up and ensure consistent end-product performance.

Strategic alliances and contract manufacturing relationships are common as companies seek to expand capacity without committing to significant capital expenditures. Smaller innovators play a meaningful role by introducing novel polymer chemistries and process innovations that incumbents may later adopt through licensing or acquisition. Value creation often centers on demonstrating robust stability data, scalable encapsulation processes, and compatibility with a range of active ingredients across pH environments.

Intellectual property around specific enteric coatings, manufacturing equipment settings, and quality control methodologies serves as another axis of competition. Firms that invest in comprehensive quality systems and transparent traceability are better positioned to win long-term contracts with regulated end users, including hospitals, research institutes, and major pharmacy chains. Ultimately, the companies that combine technical rigor, supply-chain resilience, and customer-centric commercialization models tend to capture leadership positions across adjacent application segments.

Actionable recommendations for industry leaders to combine material innovation, agile manufacturing, and strategic partnerships to build competitive moats

Leaders in the enteric capsule space should pursue an integrated strategy that balances material innovation, supply chain resilience and regulatory readiness to capture emerging opportunities. Investing in alternative, non-animal polymer development and validating those materials across multiple active ingredients can open new customer segments while reducing exposure to supply shocks tied to animal gelatin sources. At the same time, building capacity for agile manufacturing and multi-site qualification helps mitigate tariff and trade risks by enabling rapid volume shifts between facilities.

Commercial teams should deepen engagement with distribution partners and e-commerce platforms to align packaging, labeling and digital content with local regulatory requirements and consumer expectations. Establishing long-term agreements with diversified suppliers and incorporating contractual protections for duties, lead times and quality standards will strengthen procurement positions. Additionally, licensing and co-development partnerships with niche innovators can accelerate time-to-market for novel formulations while preserving capital for targeted investments.

Finally, companies should prioritize data-driven quality systems and invest in dissolution testing, stability programs and robust documentation to facilitate fast regulatory approvals and build trust with institutional buyers. By combining technical validation, flexible manufacturing footprints and strategic commercial alignment, industry leaders can reduce risk and accelerate adoption across pharmaceuticals, nutraceuticals, food and animal health applications.

A rigorous mixed-methods research methodology explaining how primary interviews, technical literature review, and data triangulation underpin the report findings

This analysis is grounded in a mixed-methods research approach combining primary and secondary evidence streams, triangulated to ensure accuracy and relevance. Primary inputs included structured interviews with formulation scientists, procurement executives, regulatory specialists and distribution partners, as well as site visits and direct observation of manufacturing processes where feasible. These engagements provided qualitative insights into material selection drivers, supply chain priorities and customer decision criteria across application areas.

Secondary research encompassed technical literature, regulatory guidance documents, industry white papers and patent filings to track material innovations and process enhancements. Publicly available company disclosures and manufacturing permits were reviewed to map capacity footprints and validate claims related to production scale and quality certifications. Data validation steps included cross-referencing supplier claims with independent laboratory test reports and corroborating interview insights against documented regulatory submissions where accessible.

Analytical methods applied a segmentation framework that connected application needs with material properties, distribution modalities and end-user procurement patterns. Limitations include potential variability in proprietary manufacturing processes and the evolving nature of tariff and regulatory interventions. To mitigate these limitations, the methodology prioritized multiple sources and emphasized transparency around data provenance and confidence levels for specific assertions.

A concise conclusion that synthesizes strategic priorities and operational imperatives for stakeholders navigating enteric capsule market complexities

In conclusion, enteric capsule technologies occupy a strategic intersection of material science, regulatory compliance and commercial distribution dynamics. Adoption is being shaped by a migration toward non-animal polymers, heightened regulatory expectations for traceability and an imperative to design resilient supply chains in the face of trade policy shifts. These forces affect decisions from early-stage formulation to procurement and downstream distribution, requiring coordinated strategies across R&D, manufacturing and commercial teams.

The most successful participants will be those that integrate technical validation with flexible manufacturing footprints and strong distribution partnerships. Embracing alternative materials that satisfy diverse consumer and regulatory needs, while maintaining rigorous quality systems, will provide both risk mitigation and differentiation. Moreover, scenario planning for trade disruptions and tariff impacts should be embedded into procurement and capital allocation decisions to preserve supply continuity and cost competitiveness.

Taken together, these insights suggest a practical roadmap: prioritize material validation, invest in quality and traceability, diversify supply sources, and align commercial approaches to the specific needs of pharmacies, hospitals, online channels and research customers. This balanced approach positions organizations to capitalize on growth opportunities while managing the operational complexities inherent to enteric capsule markets.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Enteric Capsule Market, by Application

  • 8.1. Animal Health
  • 8.2. Food & Beverages
  • 8.3. Nutraceuticals
    • 8.3.1. Herbal Products
    • 8.3.2. Vitamins & Supplements
  • 8.4. Pharmaceuticals
    • 8.4.1. Over-The-Counter Drugs
    • 8.4.2. Prescription Drugs

9. Enteric Capsule Market, by Material Type

  • 9.1. Gelatin
    • 9.1.1. Bovine Gelatin
    • 9.1.2. Porcine Gelatin
  • 9.2. Hydroxypropyl Methylcellulose

10. Enteric Capsule Market, by Distribution Channel

  • 10.1. Online
  • 10.2. Offline

11. Enteric Capsule Market, by End User

  • 11.1. Hospitals & Clinics
  • 11.2. Online Pharmacies
  • 11.3. Pharmacies & Drug Stores
    • 11.3.1. Chain Pharmacies
    • 11.3.2. Independent Pharmacies
  • 11.4. Research Institutes

12. Enteric Capsule Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Enteric Capsule Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Enteric Capsule Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Enteric Capsule Market

16. China Enteric Capsule Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Aenova Group
  • 17.6. AstraZeneca
  • 17.7. BASF SE
  • 17.8. CapsCanada Corp
  • 17.9. CAPTEK Softgel International
  • 17.10. Catalent, Inc.
  • 17.11. Cipla Limited
  • 17.12. Colorcon, Inc.
  • 17.13. Dr. Reddy's Laboratories Ltd.
  • 17.14. Eli Lilly and Company
  • 17.15. EuroCaps Ltd.
  • 17.16. Evonik Industries
  • 17.17. Fuji Capsule Co., Ltd.
  • 17.18. Gelita AG
  • 17.19. Johnson & Johnson
  • 17.20. Lonza Group Ltd.
  • 17.21. Lupin Limited
  • 17.22. Merck & Co.
  • 17.23. Natural Capsules Limited
  • 17.24. Novartis AG
  • 17.25. Pfizer Inc.
  • 17.26. Procaps Group
  • 17.27. Sirio Pharma Co., Ltd.
  • 17.28. Sun Pharmaceutical Industries Ltd.
  • 17.29. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENTERIC CAPSULE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENTERIC CAPSULE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ENTERIC CAPSULE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY MATERIAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ENTERIC CAPSULE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ENTERIC CAPSULE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ENTERIC CAPSULE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY ANIMAL HEALTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY ANIMAL HEALTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY ANIMAL HEALTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY FOOD & BEVERAGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY FOOD & BEVERAGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY FOOD & BEVERAGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY NUTRACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY NUTRACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY NUTRACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY HERBAL PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY HERBAL PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY HERBAL PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY VITAMINS & SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY VITAMINS & SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY VITAMINS & SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY PRESCRIPTION DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY PRESCRIPTION DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY GELATIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY GELATIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY GELATIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY GELATIN, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY BOVINE GELATIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY BOVINE GELATIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY BOVINE GELATIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY PORCINE GELATIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY PORCINE GELATIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY PORCINE GELATIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY HYDROXYPROPYL METHYLCELLULOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY HYDROXYPROPYL METHYLCELLULOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY HYDROXYPROPYL METHYLCELLULOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY PHARMACIES & DRUG STORES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY PHARMACIES & DRUG STORES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY PHARMACIES & DRUG STORES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY PHARMACIES & DRUG STORES, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS ENTERIC CAPSULE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS ENTERIC CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS ENTERIC CAPSULE MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS ENTERIC CAPSULE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS ENTERIC CAPSULE MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS ENTERIC CAPSULE MARKET SIZE, BY GELATIN, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS ENTERIC CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS ENTERIC CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS ENTERIC CAPSULE MARKET SIZE, BY PHARMACIES & DRUG STORES, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA ENTERIC CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA ENTERIC CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA ENTERIC CAPSULE MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA ENTERIC CAPSULE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA ENTERIC CAPSULE MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA ENTERIC CAPSULE MARKET SIZE, BY GELATIN, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA ENTERIC CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA ENTERIC CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA ENTERIC CAPSULE MARKET SIZE, BY PHARMACIES & DRUG STORES, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA ENTERIC CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA ENTERIC CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA ENTERIC CAPSULE MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA ENTERIC CAPSULE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA ENTERIC CAPSULE MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA ENTERIC CAPSULE MARKET SIZE, BY GELATIN, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA ENTERIC CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA ENTERIC CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA ENTERIC CAPSULE MARKET SIZE, BY PHARMACIES & DRUG STORES, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA ENTERIC CAPSULE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA ENTERIC CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA ENTERIC CAPSULE MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ENTERIC CAPSULE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ENTERIC CAPSULE MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ENTERIC CAPSULE MARKET SIZE, BY GELATIN, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ENTERIC CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ENTERIC CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ENTERIC CAPSULE MARKET SIZE, BY PHARMACIES & DRUG STORES, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE ENTERIC CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE ENTERIC CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE ENTERIC CAPSULE MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE ENTERIC CAPSULE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE ENTERIC CAPSULE MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE ENTERIC CAPSULE MARKET SIZE, BY GELATIN, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE ENTERIC CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE ENTERIC CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE ENTERIC CAPSULE MARKET SIZE, BY PHARMACIES & DRUG STORES, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST ENTERIC CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST ENTERIC CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST ENTERIC CAPSULE MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST ENTERIC CAPSULE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST ENTERIC CAPSULE MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST ENTERIC CAPSULE MARKET SIZE, BY GELATIN, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST ENTERIC CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST ENTERIC CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST ENTERIC CAPSULE MARKET SIZE, BY PHARMACIES & DRUG STORES, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA ENTERIC CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA ENTERIC CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA ENTERIC CAPSULE MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA ENTERIC CAPSULE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA ENTERIC CAPSULE MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA ENTERIC CAPSULE MARKET SIZE, BY GELATIN, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA ENTERIC CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA ENTERIC CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA ENTERIC CAPSULE MARKET SIZE, BY PHARMACIES & DRUG STORES, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC ENTERIC CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC ENTERIC CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC ENTERIC CAPSULE MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC ENTERIC CAPSULE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC ENTERIC CAPSULE MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC ENTERIC CAPSULE MARKET SIZE, BY GELATIN, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC ENTERIC CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC ENTERIC CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC ENTERIC CAPSULE MARKET SIZE, BY PHARMACIES & DRUG STORES, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN ENTERIC CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN ENTERIC CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN ENTERIC CAPSULE MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN ENTERIC CAPSULE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN ENTERIC CAPSULE MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN ENTERIC CAPSULE MARKET SIZE, BY GELATIN, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN ENTERIC CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN ENTERIC CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN ENTERIC CAPSULE MARKET SIZE, BY PHARMACIES & DRUG STORES, 2018-2032 (USD MILLION)
  • TABLE 153. GCC ENTERIC CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GCC ENTERIC CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. GCC ENTERIC CAPSULE MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 156. GCC ENTERIC CAPSULE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 157. GCC ENTERIC CAPSULE MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC ENTERIC CAPSULE MARKET SIZE, BY GELATIN, 2018-2032 (USD MILLION)
  • TABLE 159. GCC ENTERIC CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. GCC ENTERIC CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. GCC ENTERIC CAPSULE MARKET SIZE, BY PHARMACIES & DRUG STORES, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION ENTERIC CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION ENTERIC CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION ENTERIC CAPSULE MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION ENTERIC CAPSULE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION ENTERIC CAPSULE MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION ENTERIC CAPSULE MARKET SIZE, BY GELATIN, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION ENTERIC CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION ENTERIC CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION ENTERIC CAPSULE MARKET SIZE, BY PHARMACIES & DRUG STORES, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS ENTERIC CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS ENTERIC CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS ENTERIC CAPSULE MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS ENTERIC CAPSULE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS ENTERIC CAPSULE MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS ENTERIC CAPSULE MARKET SIZE, BY GELATIN, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS ENTERIC CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS ENTERIC CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS ENTERIC CAPSULE MARKET SIZE, BY PHARMACIES & DRUG STORES, 2018-2032 (USD MILLION)
  • TABLE 180. G7 ENTERIC CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. G7 ENTERIC CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. G7 ENTERIC CAPSULE MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 183. G7 ENTERIC CAPSULE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 184. G7 ENTERIC CAPSULE MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. G7 ENTERIC CAPSULE MARKET SIZE, BY GELATIN, 2018-2032 (USD MILLION)
  • TABLE 186. G7 ENTERIC CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. G7 ENTERIC CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. G7 ENTERIC CAPSULE MARKET SIZE, BY PHARMACIES & DRUG STORES, 2018-2032 (USD MILLION)
  • TABLE 189. NATO ENTERIC CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. NATO ENTERIC CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. NATO ENTERIC CAPSULE MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 192. NATO ENTERIC CAPSULE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 193. NATO ENTERIC CAPSULE MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. NATO ENTERIC CAPSULE MARKET SIZE, BY GELATIN, 2018-2032 (USD MILLION)
  • TABLE 195. NATO ENTERIC CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. NATO ENTERIC CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. NATO ENTERIC CAPSULE MARKET SIZE, BY PHARMACIES & DRUG STORES, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL ENTERIC CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES ENTERIC CAPSULE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES ENTERIC CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES ENTERIC CAPSULE MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES ENTERIC CAPSULE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES ENTERIC CAPSULE MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES ENTERIC CAPSULE MARKET SIZE, BY GELATIN, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES ENTERIC CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES ENTERIC CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES ENTERIC CAPSULE MARKET SIZE, BY PHARMACIES & DRUG STORES, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA ENTERIC CAPSULE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA ENTERIC CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA ENTERIC CAPSULE MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA ENTERIC CAPSULE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA ENTERIC CAPSULE MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA ENTERIC CAPSULE MARKET SIZE, BY GELATIN, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA ENTERIC CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA ENTERIC CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA ENTERIC CAPSULE MARKET SIZE, BY PHARMACIES & DRUG STORES, 2018-2032 (USD MILLION)